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Background: Infections caused by bacteria such as multidrug resistant (MDR) Acinetobacter spp. and methicillin-
resistant Staphylococcus aureus (MRSA) constitute a worldwide pandemic. Without gathering information about
these strains, we cannot reduce the morbidity and mortality due to infections caused by these notorious bugs.
Methods: This study was conducted to identify the status of MDR Acinetobacter spp. and MRSA in a tertiary care
centre of Nepal. Sputum, endotracheal aspirate and bronchial washing specimens were collected and processed
from patients suspected of lower respiratory tract infection following standard microbiological methods
recommended by the American Society for Microbiology (ASM). Double disk synergy test method was employed
for the detection of extended-spectrum beta-lactamase (ESBL) in Acinetobacter isolates. Methicillin resistance in S.
aureus was confirmed by using cefoxitin and oxacillin disks.
Results: Different genomespecies of Acinetobacter were isolated; these consisted of Acinetobacter calcoaceticus
baumannii complex and A. lwoffii. Around 95% of Acinetobacter isolates were MDR, while 12.9% were ESBL-
producer. Of the total 33 isolates of S. aureus, 26 (78.8%) were MDR and 14 (42.4%) were methicillin resistant.
Conclusions: A large number of MDR Acinetobacter spp. and MRSA has been noted in this study. The condition is
worsened by the emergence of ESBL producing Acinetobacter spp. Hence, judicious use of antimicrobials is
mandatory in clinical settings. Moreover, there should be vigilant surveillance of resistant clones in laboratories.
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Worldwide emergence of multidrug resistance among
gram-negative and gram-positive bacteria has resulted in a
confounding scene in treatment modalities. Bacteria like
Acinetobacter calcoaceticus baumannii (Acb) complex
and methicillin resistant Staphylococcus aureus (MRSA)
have created a dilemma regarding the appropriate anti-
biotic therapy to use against them. Infections caused by
these bugs are often difficult to treat. Further, these bac-
teria survive for a long time in hospital environment, with
enhanced opportunities for transmission between patients* Correspondence: smishra7@hotmail.com
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reproduction in any medium, provided the or[1]. It is noteworthy that hospital-acquired pneumonia
(HAP) developing ≥ 5 days after hospitalization (late-on-
set) is often caused by aerobic gram-negative bacilli
(e.g., Acinetobacter spp.) or MRSA [2].
MRSA is one of the most important nosocomial path-
ogens worldwide, but recently it is increasingly identified
as the etiological agent of infections acquired in commu-
nity. Molecular epidemiological studies indicate that
community associated (CA)-MRSA and healthcare asso-
ciated (HA)-MRSA may have distinctive phenotypic and
genetic features [3]. Traditionally, CA-MRSA are attrib-
uted with characteristics, such as smaller staphylococcal
chromosomal cassette (SCC)mec cassettes – types IV
and V – and a more restricted resistance pattern to anti-
biotics other than β-lactams than HA-MRSA. However,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mishra et al. BMC Research Notes 2013, 6:98 Page 2 of 6
http://www.biomedcentral.com/1756-0500/6/98recently, a bidirectional crossing of borders between
HA- and CA-associated infections is occurring [4].
These days, MRSA infections acquired outside of the
hospital setting have been increasingly reported. The re-
sistance of MRSA against various antimicrobials is glo-
bally increasing at an alarming rate. As a result,
treatment of MRSA infections has become more chal-
lenging. This is a disturbing revelation and a major con-
cern among health care professionals.
Studies of multidrug resistant (MDR) bacterial isolates
like Acb complex and MRSA are crucial not only for the
proper management of infections caused by them, but
also for the prevention of the dissemination of such
strains in the community and in hospitals. We under-
took this study to find out the current trend of drug re-
sistant Acinetobacter spp. and MRSA isolates in clinical
samples from patients suspected of lower respiratory
tract infections (LRTIs). Additionally, we aimed to deter-
mine the prevalence of ESBL in Acinetobacter and to
compare the role of oxacillin and cefoxitin discs in
detecting methicillin resistance in S. aureus.
Methods
A hospital-based prospective study was carried out in
the Bacteriology Laboratory of Tribhuvan University
Teaching Hospital (TUTH) in Kathmandu, Nepal over a
period of six months. During the study period, 1120
specimens were processed.
Inclusion criteria
Specimens obtained from the lower respiratory tract [spu-
tum, endotracheal (ET) secretion and bronchial washing]
were included for culture and sensitivity test. Only those
specimens which met the criteria recommended by the
American Society for Microbiology (ASM) [5] were se-
lected for further processing.
Culture of the specimen and identification of isolated
organisms
The specimens were cultured on Chocolate agar (CHA),
5% Sheep Blood agar (BA) and MacConkey agar (MA)
(Oxoid, UK) plates. The CHA plates were incubated in a
CO2 incubator (10% CO2) at 37°C for 24 hours. The BA
and MA plates were incubated at 37°C for 24 hours in
an aerobic atmosphere. Identification of significant iso-
lates was done following standard microbiological tech-
niques [5]. A purity plate was employed to ensure that
the inoculum used for the biochemical tests was pure.
Duplicate isolates from the same patient were ex-
cluded from the study.
Antibiotic susceptibility testing
The antibiotic sensitivity test of the pathogens isolated
from the clinical specimen was done in Mueller Hintonagar (MHA) (Oxoid, UK) by Kirby-Bauer method, as
recommended by Clinical and Laboratory Standards In-
stitute (CLSI) [6].
For disk susceptibility testing, penicillin, amoxycillin,
oxacillin, ciprofloxacin, cotrimoxazole, cephalexin, gentami-
cin, erythromycin, clindamycin, teicoplanin, vancomycin,
amoxicillin-clavulanate, cloxacillin, linezolid and cefoxitin
were used for S. aureus. Likewise, ciprofloxacin, cotri-
moxazole, gentamicin, amikacin, cefotaxime, ceftriaxone,
ceftazidime, cefepime, amoxicillin-clavulanate, piperacillin,
piperacillin-tazobactam, tigecycline,cefoperazone-sulbactam,
meropenem and imipenem were used for Acinetobacter
spp. The initial screen test for the production of ESBL was
performed by using ceftriaxone (CRO) (30 μg), cef-
tazidime (CAZ) (30 μg) and cefotaxime (CTX) (30 μg)
disks (Oxoid, UK). If the zone of inhibition (ZOI) was
≤ 25 mm for CRO, ≤ 22 mm for CAZ and/or ≤ 27 mm for
CTX, the isolate was considered a potential ESBL-
producer as recommended by CLSI [6]. Isolates those that
were suspected as ESBL-producer by screen test were
tested further by double disk synergy test (DDST). In
DDST method, amoxicillin-clavulanic acid (AMC) disk
(20/10 μg) was placed at the center and disks containing
the 30 μg of CAZ, CTX and CRO were placed separately
beside 15 mm distance (edge to edge), away from the cen-
tral disk, in a horizontal manner [7]. Any enhancement of
the ZOI between the disks (either of the cephalosporin
disks and clavulanic acid containing disk) indicated the
presence of ESBL.
In this study, if the isolates were resistant to at least
three classes of first line antimicrobial agents, they were
regarded as MDR [8]. Inducible macrolide-lincosamide-
streptogramin B (iMLSB) resistance was detected in S.
aureus by Disk approximation test placing a 2 micro-
gram clindamycin disk 15 mm away from the edge of a
15 microgram erythromycin disk on a MHA plate. Fol-
lowing incubation, organisms that showed flattening of
the clindamycin zone adjacent to the erythromycin disk
(referred to as a "D" zone) were considered to exhibit in-
ducible clindamycin resistance [6].
To test for MRSA, a 1 μg oxacillin disk and a 30 μg
cefoxitin disk were used, and the plates were incubated
at 35°C. Plates containing oxacillin disk were read fol-
lowing a 24 hour incubation period. The diameter of the
ZOI of growth was recorded and interpreted as suscep-
tible or resistant by the criteria of CLSI. S. aureus iso-
lates were deemed methicillin resistant when the ZOI
was ≤10 mm with the oxacillin disk test or ≤21 mm with
the cefoxitin disk method [6].
Control strains of E. coli ATCC 25922 and S. aureus
ATCC 25923 were used for the standardization of the
antibiotic sensitivity test. For ESBL test standardization,
E. coli ATCC 25922 and K. pneumoniae ATCC 700603
were used as negative and positive controls respectively.
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used as negative and positive controls respectively for
MRSA test standardization.
Ethical consideration
Permission was obtained from the Institutional Review
Board at the Institute of Medicine, Tribhuvan University,
Kathmandu. Written informed consent for participation
in the study was obtained from participants or where
participants were children, the consent was obtained
from their parent or guardian.
Data processing and analysis
Data were analyzed using Microsoft Excel 2007 and rep-
resented as frequency distribution and percentage.
Results
Number of specimens and result pattern
Among the total processed specimens (n=1120), 497
showed significant growth (44.38%). Of all the isolates,
Acinetobacter spp., the organism of our interest, was
the fourth most common bacterial isolate (11.23%).
Acinetobacter spp. comprised of both Acb complex and
A. lwoffii. Likewise, S. aureus was the seventh most
common significant bacteria (6.19%) to cause LRTIs. A
majority of Acinetobacter spp. (88.3%) and S. aureus
(75.76%) were isolated from inpatients.
Antimicrobial susceptibility test result of Acinetobacter
spp.
Nearly 58%, 38.7% and 35% of Acinetobacter isolates

















Tigecycline 38.7and imipenem respectively (Table 1). Approximately
95% of Acinetobacter isolates were MDR, while 12.9%
were ESBL-producer (Data not shown in table).Antimicrobial susceptibility test result of S. aureus
Most of the commonly used oral antibiotics were not ef-
fective against S. aureus. Only vancomycin, teicoplanin
and linezolid were found to be the most effective antibi-
otics (Table 2).MRSA and Inducible clindamycin resistance
Of the total 33 isolates of S. aureus, 14 (42.4%) were
methicillin-resistant. Incidence of inducible clindamycin
resistance was also seen (3.0%).Number of MDR bacterial isolates
Nearly 95% of Acinetobacter spp. and 78.8% of S. aureus
isolates were MDR.Distribution of Acinetobacter and MRSA
Acinetobacter spp. and MRSA were more common in in-
tensive care units (ICUs) (Table 3).Comparison of Cefoxitin and Oxacillin methods for MRSA
detection
Among the 33 S. aureus isolates subjected to the
cefoxitin (30 μg) and oxacillin (1 μg) disk methods, the
former detected 14 (42.4%) to be MRSA and the latter
detected 12 (36.4%). The cefoxitin disk method detected


















Table 3 Wardwise distribution of ESBL- producing
Acinetobacter spp. and MRSA




Cardiac care unit (CCU) 5 1
ICU 23 6
Mishra et al. BMC Research Notes 2013, 6:98 Page 4 of 6
http://www.biomedcentral.com/1756-0500/6/98Discussion
This study was conducted among the patients attending
TUTH, Kathmandu to find out the bacteriology of
LRTIs with special reference to Acinetobacter spp. and
MRSA.
A higher prevalence of Acinetobacter spp. was encoun-
tered in this study. Acinetobacter spp. consisted of Acb
complex (10.85%) and A. lwoffii (0.38%). A prevalence
study carried out a decade ago at TUTH showed the
growth of Acinetobacter spp. to be 1.19% of the total
number of cases [9]. Another study in the same setting
in 2004 showed the increment in growth of these bac-
teria by twofold [10]. Likewise, the present finding on
the prevalence of Acinetobacter spp. is higher than
reported 3.9% of LRTI cases in Western Nepal [11].
These findings show an increasing trend in the preva-
lence of Acinetobacter spp.
In this study, out of total 62 Acinetobacter isolates, 51
(85.0%) were from inpatients and 48 (77.42%) were from
elderly patients. The infection caused by Acinetobacter
most frequently involved the respiratory tract of intubated
patients. Studies have shown that Acinetobacter pneumo-
nia is more common in critically ill patients in Asian
(range 4-44%) and European hospitals (0-35%); however, it
has a low incidence in United States hospitals (6-11%) [12].
Fluoroquinolones have replaced other quinolones over
the last two decades. They are now widely used in clin-
ical medicine as broad-spectrum antimicrobial agents.
As a result, fluoroquinolone resistance is increasing rap-
idly [13]. In our study, ciprofloxacin resistance was
found in 64.52% of Acinetobacter spp. isolates. Higher
resistance (72.9% and (>90%) to this antibiotic has been
reported in India by Joshi et al. [13] and Mezzatesta
et al. [14]. Acinetobacter spp. are known to harbour re-
sistance plasmids (R-plasmids), and therefore often act
as a reservoir of multidrug-resistance [15]. These patho-
gens can mutate to acquire quinolone resistance by ei-
ther target alteration that modifies DNA gyrase (DNA
topoisomerase II), or diminished drug accumulation by
modifying porin system and efflux pump [16].
Out of 62 Acinetobacter isolates, 59 (95.16%) were MDR
and 88.14% of the MDR Acinetobacter isolates were from
inpatients. This startling rate of MDR Acinetobacter un-
derscores the need for a cogent step in treatment options.Higgins et al. [16] suggested that sulbactam had better ac-
tivity over clavulanate and tazobactam and it might repre-
sent an alternative treatment option for infections due to
the MDR Acb complex. Ling et al. [17] also reported a
higher sensitivity of Acb complex against cefoperazone-
sulbactam than piperacillin-tazobactam in Shanghai
(91% vs. 29%) and Hong-Kong (95% vs. 81%). Comply-
ing with the previous studies, this study also showed
cefoperazone-sulbactam had a comparatively lower re-
sistance rate (54.84%) than piperacillin-tazobactam
(58.07%) and amoxycillin-clavulanate (88.71%); however,
the difference is not significant for the former.
Tigecycline, a glycylcycline, was found to be a promising
antibiotic. However, caution should be used in consider-
ing tigecycline treatment for A. baumannii infection in
sites where drug levels may be suboptimal, such as the
bloodstream. Development of resistance to tigecycline
has been reported recently [18].This demands prudent
use of this novel antibiotic in treatment modalities.
The resistance of Acinetobacter spp. towards the
carbapenems is much higher in this study (50% for
meropenem and 35.48% for imipenem) as compared to
different studies in Indian hospitals, viz., All India Insti-
tute of Medical Sciences (34.7% for meropenem and
27.2% for imipenem) [19], and St. John’s Hospital (14.0%
for meropenem) [20].
The decreased susceptibility of gram-negative isolates
towards the third and fourth generation cephalosporins
(26.79% to 28.57%) could be attributable to ESBL or
AmpC beta-lactamase production. We found that 12.9%
of Acb complex were ESBL-producer. However, we did
not perform test for AmpC beta lactamase. Due to the in-
crease in ESBL producing strains, there has been increased
use of beta-lactam/ beta-lactamase inhibitor combinations,
monobactams and carbapenems. However, the last few
years have witnessed an increasing resistance to these
drugs as well. In India, 22.2% and 17.3% of ESBL producers
showed resistance to meropenem and imipenem respect-
ively [19]. Though this reported finding is slightly higher
than the present study finding, the possibility of the emer-
gence of carbapenem-resistant isolates cannot be denied.
Medical wards and ICUs comprised the major domicile
of ESBL producers. Third generation cephalosporin, such
as ceftriaxone, cefotaxime and ceftazidime, are highly used
in ICUs, even in our setting. Therefore, the resistance ob-
served here may have appeared under the selective influ-
ence of the extensive usage of these antibiotics. In any
nosocomial setting, carbapenems are used as the last re-
sort for treatment of MDR Acinetobacter infections. How-
ever, over the last 15 years, acquired resistance to this life
saving antimicrobial has been increasingly reported [21].
The pan-resistant gram-negative ESBL producing isolates
were sensitive to polymyxin B and colistin sulphate. Be-
cause no fundamentally new anti-infective drugs are
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drugs’ and, fortunately, they proved to be as effective in
this study as in other studies [22].
Apart from drug resistance in gram-negative bacteria,
a worldwide increase in antibiotic resistance has been
observed among gram-positive isolates. Today the con-
cern of MRSA has reached the pinnacle. It is noteworthy
that MRSA can cause both community- and hospital-
acquired infections. However, there are only a few re-
ports depicting the situation of MRSA among LRTI
isolates in Nepal. In this study, out of total 33 S. aureus
isolates, 14 (42.42%) were identified as MRSA. Nearly
93% of MRSA were isolated from inpatients (P<0.04).
Considering the specimenwise distribution, 78.59% of
the MRSA were isolated from sputum specimens, while
the rest were from ET secretion. In eastern Nepal,
Kumari et al. found that 60% of S. aureus isolates from
respiratory tract specimens were methicillin resistant.
Though the finding of the present study showed less
prevalence of MRSA as compared to Kumari et al. [23],
it is much higher than that of 13.01% reported by
Pokhrel et al. [24] from TUTH in 1993 and 15.4% by
Subedi et al. [25] from Western Nepal in 2005.
Prior antibiotic use is the most common risk factor for
colonization and infection with MRSA. Other risk
factors for pneumonia due to MRSA include use of cor-
ticosteroids and chronic obstructive pulmonary disease.
Mortality rates are higher in patients with pneumonia
caused by MRSA than in those with pneumonia caused
by methicillin susceptible S. aureus [26]. This heightened
mortality likely reflects more serious comorbidities ra-
ther than differences in the virulence of the organisms
[27]. In Japan, MRSA isolates from sputum specimens dra-
matically increased from 0% in 1985 to 51.4% in 1988.
Moreover, 7 out of 13 cases of bronchopulmonary infec-
tions due to MRSA died [28]. The SENTRY antimicrobial
surveillance (1997–1999) program found that the preva-
lence of MRSA in hospitals was very high in Singapore
(62.9%), Taiwan (61.1%) and Portugal (54.4%) [29].
This study demonstrated that the overall sensitivity
pattern of S. aureus isolates, with the exception to
clindamycin, linezolid, teicoplanin, and vancomycin, other
commonly prescribed antibiotics, had their spectrum of
action much below 70%. Nearly 54.54% of the isolates
were sensitive to clindamycin and 100% to linezolid,
teicoplanin and vancomycin. Agents like erythromycin,
ciprofloxacin and cotrimoxazole were effective in only
36.36%, 30.30%, and 27.27% cases, respectively. Resistance
to penicillin was found in 93.94% of the S. aureus isolates.
This finding complies with that of Dar et al. [30], who
showed 92.0% of the S. aureus were resistant to penicillin.
In this study, a very low sensitivity of MRSA strains
towards ciprofloxacin is probably due to the indiscrimin-
ate empirical use of these drugs because of their low costand ease of availability in our country. High resistance to
ciprofloxacin has also been observed by Subedi et al.
[25]. The susceptibility towards erythromycin was also
lower in this study when compared with that of Kumari
et al. (28.69%) [23]. Clindamycin is one of the drugs of
choice in MRSA infections. Macrolide-resistant isolates
of S. aureus may have constitutive or inducible resist-
ance to clindamycin (methylation of the 23S rRNA
encoded by the erm gene also referred to as MLSB i.e.,
Macrolide, Lincosamide and type B Streptogramin resist-
ance) or may be resistant only to macrolides (efflux
mechanism encoded by the msrA gene) [6]. In this
study, one erythromycin inducible clindamycin resistant
case in an MRSA strain was also observed by D test.
Vancomycin is used to treat MDR infections. In this
study, no isolate was found to be vancomycin resistant.
Vancomycin seemed to be the only option as the last re-
sort antibiotic for MDR staphylococcal infection.
Two different methods were employed for the detec-
tion of MRSA. The cefoxitin disk method was better
than the oxacillin disk method (P>0.05), as the former
detected all 14 MRSA cases while the latter missed two
cases. According to CLSI [6], the cefoxitin disk test is
comparable to the oxacillin disk test for the prediction
of mecA-mediated resistance to oxacillin. The cefoxitin
disk test is easier to read and thus is the preferred method.
Besides, cefoxitin is an inducer of the mecA gene.
Conclusions
Notorious bugs such as MDR Acinetobacter spp. and
MRSA have emerged. Although combination drugs and
carbapenems are relatively more effective against
Acinetobacter spp., there is a confounding scene in anti-
biotic armamentarium due to reports on resistance of
these bugs against the last resort antibiotics. Thus, there is
a great threat of dissemination of such resistant clones in
the community as well as in hospital settings. It is
mandatory to control this situation before it leads to a dis-
aster. Hospital infection control program should be effect-
ively implemented for the management of infected patients
and to breach the transmission of such organisms to other
patients, health care workers, and to the community.
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